$9 billion to $10 billion is the price range GSK is discussing for cancer drug developer Nuvalent, with talks active late Monday, the Financial Times reported.
An agreement could be reached as soon as this week, according to people familiar with the matter cited by the newspaper.
Last-minute hurdles still threaten the negotiations, and the discussions could yet collapse despite the accelerated timeline.
The potential acquisition would expand GSK's oncology portfolio through a biotech focused on cancer treatments.